Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
RESEARCH TOOLSreports
Holding LQDA?
Track your performance easily
Earnings Data
Report Date
Mar 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.39Last Year’s EPS
-$0.43Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: 4.42%
|Next Earnings Date:Mar 13, 2025
Earnings Call Sentiment|Neutral
The earnings call expressed optimism about Liquidia's strategic and clinical progress, particularly in advancing YUTREPIA towards approval and expanding partnerships. However, ongoing legal challenges and increased expenses pose significant hurdles.Company Guidance
During the Liquidia Corporation's Q3 2024 earnings call, the executives provided substantial guidance on the company's progress and future outlook. They highlighted significant milestones, including the pathway to final approval for YUTREPIA, pending the expiration of TYVASO DPI's clinical exclusivity on May 23, 2025. The call detailed the company's clinical advancements, such as enrolling over one-third of patients in the ASCENT study for PH-ILD, with expectations to complete enrollment by Q1 2025. Financially, Liquidia reported $4.4 million in revenue for the quarter, an increase from $3.7 million a year prior, and ended the quarter with $204.4 million in cash, following $100 million raised through recent financings. The executives discussed ongoing legal proceedings with the FDA, anticipating a summary judgment hearing on December 5, 2024, which could potentially expedite YUTREPIA's market entry. They also mentioned the positive trajectory of their L606 program, planning a pivotal global Phase III study in PH-ILD patients.Progress Towards YUTREPIA Approval
Liquidia Corporation is on track to receive final approval for YUTREPIA for PAH and PH-ILD patients following the expiration of TYVASO DPI's clinical exclusivity on May 23, 2025.
Successful Legal Outcomes
The Supreme Court's decision has exhausted the legal process regarding three patents initially asserted against Liquidia, removing impediments to YUTREPIA's commercialization.
Positive Clinical Developments
The ASCENT study has shown encouraging preliminary data on YUTREPIA's safety and efficacy in PH-ILD patients, with 1/3 of patients enrolled and high tolerability noted.
Expanded Partnerships and Resources
Liquidia expanded its relationship with Pharmosa, including a license agreement for L606 in the EU and other territories, and secured rights to a next-generation nebulizer.
Strengthened Financial Position
The company closed several financings, bringing in approximately $100 million, and ended Q3 2024 with $204.4 million in cash, supporting its corporate objectives.
Revenue Growth
Q3 2024 revenue increased to $4.4 million from $3.7 million in Q3 2023, largely due to higher sales quantities from the promotion agreement with Sandoz.
---
LQDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
LQDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $10.63 | $10.27 | -3.39% |
| Aug 07, 2024 | $11.06 | $10.68 | -3.44% |
| May 13, 2024 | $12.14 | $11.96 | -1.48% |
| Mar 13, 2024 | $13.98 | $14.73 | +5.36% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Liquidia Technologies Inc (LQDA) report earnings?
Liquidia Technologies Inc (LQDA) is schdueled to report earning on Mar 13, 2025, TBA Not Confirmed.
What is Liquidia Technologies Inc (LQDA) earnings time?
Liquidia Technologies Inc (LQDA) earnings time is at Mar 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LQDA EPS forecast?
LQDA EPS forecast for the fiscal quarter 2024 (Q4) is -$0.39.
---